Abstract: The present invention provides a fusion protein of an antigen-binding protein and a fluorescent protein or a fluorescence-labeled tag protein. The present invention provides a fusion protein of an antigen-binding protein and a fluorescent protein or a fluorescence-labeled tag, wherein the antigen-binding protein is an antigen-binding protein having a helix structure or a ?-sheet structure at a terminus, the fluorescent protein or the fluorescence-labeled tag is a fluorescent protein or a fluorescence-labeled tag having a helix structure or a ?-sheet structure at a terminus, and the helix at the terminus and the helix at the terminus are linked, or the ?-sheet structure at the terminus and the ?-sheet structure at the terminus are linked.

Abstract: Components that demonstrate an ?-glucosidase inhibitory activity and hyperglycemic inhibitory activity have clearly been provided from among the components included in Yacon. The present inventors found that as a result of screening for a strong anti-oxidant component in a Yacon aerial portion extract, an antioxidant activity was converged in a DIAION HP-20 column chromatography 50% methanol-eluted fraction of hot water extract. Thus, since a previously unidentified high-content component was confirmed, the present inventors conducted purification thereof, and thereby separated TCAA. As a result, this TCAA was found to be the component that demonstrates the ?-glucosidase inhibitory activity and hyperglycemic inhibitory activity.

Abstract: An O-aryl N-(6-alkoxy-2-pyridyl)-N-alkylthiocarbamate represented by the following formula (I): (wherein R1, R2 and Ar are as defined below) is produced by treating a phenol represented by the following general formula (IV): Ar—OH??(IV) (wherein Ar represents an aryl group) with a base in a solvent and then adding thereto an alkali metal salt of N-(6-alkoxy-2-pyridyl)-N-alkyldithiocarbamic acid represented by the following general formula (III): (wherein R1 and R2 independently represent a C1-C4 alkyl group and M represents an alkali metal) and a halomethane represented by the following general formula (V): CH2XmYn??(V) (wherein X and Y represent different halogen atoms, m represents 0, 1 or 2, n represents 0, 1 or 2, and m+n equals 2) for causing a reaction.

Abstract: An O-aryl N-(6-alkoxy-2-pyridyl)-N-alkylthiocarbamate represented by the following formula (I): (wherein R1, R2 and Ar are as defined below) is produced by treating a phenol represented by the following general formula (IV): Ar—OH ??(IV) (wherein Ar represents an aryl group) with a base in a solvent and then adding thereto an alkali metal salt of N-(6-alkoxy-2-pyridyl)-N-alkyldithiocarbamic acid represented by the following general formula (III): (wherein R1 and R2 independently represent a C1-C4 alkyl group and M represents an alkali metal) and a halomethane represented by the following general formula (V): CH2XmYn ??(V) (wherein X and Y represent different halogen atoms, m represents 0, 1 or 2, n represents 0, 1 or 2, and m+n equals 2) for causing a reaction.

Abstract: Components that demonstrate an ?-glucosidase inhibitory activity and hyperglycemic inhibitory activity have clearly been provided from among the components included in Yacon. The present inventors found that as a result of screening for a strong anti-oxidant component in a Yacon aerial portion extract, an antioxidant activity was converged in a DIAION HP-20 column chromatography 50% methanol-eluted fraction of hot water extract. Thus, since a previously unidentified high-content component was confirmed, the present inventors conducted purification thereof, and thereby separated TCAA. As a result, this TCAA was found to be the component that demonstrates the ?-glucosidase inhibitory activity and hyperglycemic inhibitory activity.

Abstract: The dielectric ceramic composition of the first aspect of the invention comprises an essential component having a compositional formula of xBaO-yTiO2-zNd2O3 (wherein 0.02≦x≦0.2, 0.6≦y≦0.8, 0.01≦z≦0.3, x+y+z=1), and contains two types of glass powder, one comprising PbO, ZnO and B2O3 and the other comprising SiO2 and B2O3, and a third component that comprises Al2O3, SrTiO3, GeO2 and Li2O. Its advantages are that it can be sintered at low temperatures, its dielectric constant &egr;r falls between 10 and 50 or so, its unloaded Q is large, and its temperature-dependent resonant frequency change is small. The dielectric ceramic composition of the second aspect of the invention comprises an essential component having a compositional formula of s(xBaO-yTiO2-zNd2O3)-tNd2Ti2O7 (wherein 0.02≦x≦0.2, 0.6≦y≦0.8, 0.01≦z≦0.3, x+y+z=1, 0.1≦s≦0.8, 0.2≦t≦0.

Abstract: The dielectric ceramic composition of the first aspect of the invention comprises an essential component having a compositional formula of xBaO-yTiO2-zNd2O3 (wherein 0.02≦x≦0.2, 0.6≦y≦0.8, 0.01≦z≦0.3, x+y+z=1), and contains two types of glass powder, one comprising PbO, ZnO and B2O3 and the other comprising SiO2 and B2O3, and a third component that comprises Al2O3, SrTiO3, GeO2 and Li2O. Its advantages are that it can be sintered at low temperatures, its dielectric constant &egr;r falls between 10 and 50 or so, its unloaded Q is large, and its temperature-dependent resonant frequency change is small.

Abstract: The present invention is directed to quinoline sulfide derivatives with antibacterial activities selectively against Hp, obtained by reacting quinoline-4(1H)-thione derivatives with halides and represented by the formula I ##STR1## wherein R.sub.1 represents hydrogen or halogen atom, C.sub.1 -C.sub.6 alkoxy, C.sub.1 -C.sub.6 alkylthio or di C.sub.1 -C.sub.6 alkylamino; R.sub.2 and R.sub.3 respectively represent hydrogen atom or C.sub.1 -C.sub.6 alkyl; one of R.sub.4 and R.sub.5 represents hydroxyl group and the other represents hydrogen atom or CR.sub.4 R.sub.5 represents carbonyl; and m and n are integers, m being 1 or 2, n being 0 or 1.